New CAR T-Cell therapy targets tough leukemia in early trial

NCT ID NCT06281847

First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 29 times

Summary

This study tests a new treatment called CCTx-001 for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The therapy uses specially engineered immune cells to find and attack leukemia cells. The trial aims to find the best dose and check if it is safe and effective in about 143 participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA REFRACTORY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Besançon Regional and University Hospital

    Besançon, France

    Contact

    Contact

  • Hospital Saint Louis

    Paris, France

    Contact

    Contact

  • Karolinska University Hospital

    Stockholm, Sweden

    Contact

    Contact

  • Ludwig-Maximilians University of Munich

    Munich, Germany

    Contact

    Contact

  • University Hospital Ulm

    Ulm, Germany

    Contact

    Contact

  • Vall d'Hebron University Hospital

    Barcelona, Spain

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.